Forever Labs will dedicate resources to continue pioneering stem cell research breakthroughs and accelerate brand development.
Founded in 2015, Forever Labs is transforming the healthcare industry by preserving healthy stem cells for future therapies that combat age-related diseases, as well as aging itself.
Its proprietary procedure involves a certified Forever Labs physician collecting one's mesenchymal stem cells (MSCs), which have the ability to stimulate tissues to grow and repair themselves when most needed.
After a brief outpatient procedure, the stem cells are cryogenically frozen and safely stored agnostically in an FDA-compliant clinical-grade biorepository until needed.
Forever Labs was created to preserve healthy stem cells to later rejuvenate one's MSC population to significantly delay the onset of those age-related diseases and extend a healthy lifespan.
Galapagos and Gilead expand collaboration to advance T cell engager programme
Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
Hengrui Pharma and Braveheart Bio report positive Phase 2 results for HRS/BHB-1893 in oHCM
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
Fusion Antibodies signs GBP250,000 IP transfer deal with Finn Therapeutics
GSK's bepirovirsen accepted for review in China as potential Hepatitis B functional cure
4DMedical secures EU approval for CT:VQ as EUR83m funding fuels European expansion
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Lunit and CellCarta partner to advance AI-driven digital pathology in CDx development